{"id":"cyclophosphamide-doxorrubicin","safety":{"commonSideEffects":[{"rate":"60–90","effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":"70–90","effect":"Nausea and vomiting"},{"rate":"80–90","effect":"Alopecia"},{"rate":"30–50","effect":"Mucositis"},{"rate":"5–20","effect":"Cardiotoxicity (doxorrubicin-related)"},{"rate":"5–10","effect":"Hemorrhagic cystitis (cyclophosphamide-related)"},{"rate":"20–40","effect":"Infection"},{"rate":"50–70","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1200796","moleculeType":"Small molecule","molecularWeight":"279.10"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclophosphamide is a nitrogen mustard alkylating agent that cross-links DNA strands, preventing replication and transcription. Doxorrubicin intercalates into DNA and inhibits topoisomerase II, blocking DNA unwinding and repair. Together, they create synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"This combination uses cyclophosphamide (an alkylating agent) and doxorrubicin (a topoisomerase II inhibitor) to damage cancer cell DNA through complementary mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:12.673Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (likely primary indication given AC regimen use)"},{"name":"Lymphomas"},{"name":"Other solid tumors"}]},"trialDetails":[{"nctId":"NCT04540692","phase":"PHASE3","title":"Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2021-01-12","conditions":"Breast Cancer","enrollment":444},{"nctId":"NCT02978495","phase":"PHASE2","title":"Neoadjuvant Carboplatin in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Barretos Cancer Hospital","startDate":"2017-05-17","conditions":"BRCA1 Hereditary Breast and Ovarian Cancer Syndrome","enrollment":154},{"nctId":"NCT01329640","phase":"PHASE2","title":"Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)","status":"TERMINATED","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2010-09","conditions":"Locally Advanced HER2-positive Breast Cancer","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Citoxan + Rubidox"],"phase":"phase_3","status":"active","brandName":"Cyclophosphamide + Doxorrubicin","genericName":"Cyclophosphamide + Doxorrubicin","companyName":"Latin American Cooperative Oncology Group","companyId":"latin-american-cooperative-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses cyclophosphamide (an alkylating agent) and doxorrubicin (a topoisomerase II inhibitor) to damage cancer cell DNA through complementary mechanisms. Used for Breast cancer (likely primary indication given AC regimen use), Lymphomas, Other solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}